Author(s)

Nesibe Karahan Yeşil¹, Hatice Şahin², Hatice Işık³, Zuhal Örnek⁴, Serpil Yazgan⁵, Adem Tok⁶, Yunus Emre Yandı⁷, Metin Işık^8*, İsmail Doğan⁹

¹Department of Rheumatology, Ankara Research and Education Hospital, Ankara, Turkey.
²Department of Internal Medicine, Faculty of Medicine, Bülent Ecevit University, Zonguldak, Turkey.
³Department of Obstetrics and Gynecology, Faculty of Medicine, Bülent Ecevit University, Zonguldak, Turkey.
⁴Department of Pediatric Disaease, Faculty of Medicine, Bülent Ecevit University, Zonguldak, Turkey.
⁵Department of Ophtalmology, Faculty of Medicine, Bülent Ecevit University, Zonguldak, Turkey.
⁶Department of Urology, Faculty of Medicine, Bülent Ecevit University, Zonguldak, Turkey.
⁷Division of Biochemistry, Department of Medical Services and Techniques, Health Sciences, Vocational School, Bülent Ecevit University, Zonguldak, Turkey.
⁸Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Bülent Ecevit University, Zonguldak, Turkey.
⁹Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Hitit University, Çorum, Turkey.

Behcet’s disease (BD) is a large vessel vasculitis with a wide range of clinical manifestations. Some of these manifestation may be life threatening and rapid suppression of the inflammation with effective immunosuppressive agent is crucial. There are traditional drugs with different response rates and all have efficacy on different manifestations of the disease. The most frightening manifestations of the disease are ocular, neurologic, intestinal and vascular types of involvement. Besides benign and easily treated manifestations there are also refractory cases with complicated involvement. The novel biologic agents have been used for these resistant patients and favorable response rates have been reported. In this review, we have shared our experience with biologic agents in BD and also reviewed the literature for the efficacy and safety for these novel agents for refractory patients.

Behçet’s Disease, Novel Biologic Agents, Refractory Patients

Yeşil, N. , Şahin, H. , Işık, H. , Örnek, Z. , Yazgan, S. , Tok, A. , Yandı, Y. , Işık, M. and Doğan, İ. (2015) Biologic Agents in Behçet’s Disease: Our Experience and Review of the Literature. Open Journal of Rheumatology and Autoimmune Diseases, 5, 97-103. doi: 10.4236/ojra.2015.54016.